Patients with relapsed/refractory CLL who received zanubrutinib achieved significantly superior PFS compared with ibrutinib. The prescribing information for Brukinsa ® (zanubrutinib) has been updated ...
A recent panel discussion set the stage for defining standards for drug approval as separate from those for treatment decisions. FDA’s success in removing Avastin’s metastatic breast cancer (MBC) ...
HONG KONG, Jan. 6, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced that the National Medical Products Administration has approved a significant label update in China for its internally developed, ...
Final CEPHEUS transplant-ineligible analysis showed 72-month PFS of 59.3% with DVRd versus 38.3% with VRd; median PFS was unreached versus 50.2 months (HR 0.55). MRD negativity improved with DVRd at ...
Regulatory Challenges: Is a Surrogate End Point Instead of Overall Survival Enough for Regulatory Approval of (Neo)Adjuvant Cancer Treatment? The Swissmedic Perspective PFS depends on evaluation of ...
Pirtobrutinib was associated with a statistically significant improvement in PFS compared with bendamustine plus rituximab therapy. Topline data were announced from a phase 3 trial evaluating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results